These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 19656718)
1. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Decker WK; Safdar A Cytokine Growth Factor Rev; 2009 Aug; 20(4):271-81. PubMed ID: 19656718 [TBL] [Abstract][Full Text] [Related]
2. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. McCarthy EF Iowa Orthop J; 2006; 26():154-8. PubMed ID: 16789469 [TBL] [Abstract][Full Text] [Related]
3. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Wiemann B; Starnes CO Pharmacol Ther; 1994; 64(3):529-64. PubMed ID: 7724661 [TBL] [Abstract][Full Text] [Related]
4. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy. Carlson RD; Flickinger JC; Snook AE Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous regression: a hidden treasure buried in time. Hoption Cann SA; van Netten JP; van Netten C; Glover DW Med Hypotheses; 2002 Feb; 58(2):115-9. PubMed ID: 11812185 [TBL] [Abstract][Full Text] [Related]
7. William Coley: The Pioneer and the Father of Immunotherapy. Munir M; Cheema AY; Ogedegbe OJ; Aslam MF; Kim S Cureus; 2024 Sep; 16(9):e69113. PubMed ID: 39391466 [TBL] [Abstract][Full Text] [Related]
12. Dr William Coley and tumour regression: a place in history or in the future. Hoption Cann SA; van Netten JP; van Netten C Postgrad Med J; 2003 Dec; 79(938):672-80. PubMed ID: 14707241 [TBL] [Abstract][Full Text] [Related]
13. Engineering Opportunities in Cancer Immunotherapy: After Decades of Missteps and Delays, a Growing Immune-Oncology Market and Improved Cancer Treatment Outcomes Open New Prospects for Biomedical Engineers and Data Scientists. Zaharoff DA IEEE Pulse; 2018; 9(4):8-11. PubMed ID: 30028678 [TBL] [Abstract][Full Text] [Related]
14. Coley's Lessons Remembered: Augmenting Mistletoe Therapy. Orange M; Reuter U; Hobohm U Integr Cancer Ther; 2016 Dec; 15(4):502-511. PubMed ID: 27207233 [TBL] [Abstract][Full Text] [Related]
15. The response of urological tumours to immunotherapy. Gkialas I; Kalantzis A; Lykourinas M J BUON; 2005; 10(3):329-36. PubMed ID: 17357186 [TBL] [Abstract][Full Text] [Related]
16. Pathogens and glioma: a history of unexpected discoveries ushering in novel therapy. Shah AH; Jusué-Torres I; Ivan ME; Komotar RJ; Kasahara N J Neurosurg; 2018 Apr; 128(4):1139-1146. PubMed ID: 28598280 [TBL] [Abstract][Full Text] [Related]
17. A. Chekhov, M.D., and Coley's toxins. Gresser I N Engl J Med; 1987 Aug; 317(7):457. PubMed ID: 3302707 [No Abstract] [Full Text] [Related]
18. [History of Immuno-therapy - from Coley Toxins to Check-points of the Immune Reaction]. Říhová B; Šťastný M Klin Onkol; 2015; 28 Suppl 4():4S8-14. PubMed ID: 26647883 [TBL] [Abstract][Full Text] [Related]